In this study, the bladder emptying methods at different stages of the post-stroke period along with the effects of demographic and clinical parameters on spontaneous voiding frequency were investigated. The frequencies of bladder emptying methods at admission to the rehabilitation clinic, after neurourological and urodynamic assessment and at home after discharge were spontaneous voiding (SV) 51/99 (51.5 %), 62/99 (62.6 %), 73/99 (73.7 %), emptying without a urinary catheter + an external collector system (EWUC + ECS) 24/99 (24.2 %), 18/99 (18.2 %), 17/99 (17.2 %), intermittent catheterization (IC) 1/99 (1.0 %), 15/99 (15.2 %), 6/99 (6.1 %), indwelling urethral catheter (IUC) 23/99 (23.2 %), 4/99 (4.0 %) and 3/99 (3.0 %), respectively. Lower spontaneous voiding frequencies were observed in single-divorced and geriatric individuals (p < 0.05). The number of patients who modified the method at home was 2/62 for SV, 5/18 for EWUC + ECS, 9/15 for IC, and 2/4 for IUC. The majority of stroke patients were able to void spontaneously and the spontaneous voiding frequency increased at follow-up. The spontaneous voiding frequency was low in geriatric and single-divorced subgroups. The method in which the most changes occurred was IC.

Objectives: This study aimed to examine whether there is an association between hip osteoarthritis and vitamin D receptor gene FokI polymorphisms. Patients and methods: In this case-control study, a total of 162 volunteers (43 males, 119 females; mean age: 62.4±9.3; range, 50 to 80 years) were included between March 2011 and March 2012. The patient group included 80 individuals with a diagnosis of coxarthrosis. Eightytwo individuals with normal hip, low back, and sacroiliac joint examination were included in the control group. The American College of Rheumatology hip osteoarthritis classification criteria were used in the diagnosis of coxarthrosis. Analysis of FokI polymorphisms was performed with restriction fragment length polymorphisms. Results: When the genotype and allele distributions of vitamin D receptor FokI polymorphisms were examined, no statistical difference was found in both groups. Conclusion: No significant association between the hip osteoarthritis and FokI polymorphisms could be obtained.

No abstract

Sjögren’s syndrome (SS) is a chronic, autoimmune, inflammatory disease characterized by lymphocytic infiltration, destruction and dysfunction of the exocrine glands. Sjögren’s syndrome can be described as primary or secondary, depending on whether it occurs alone or in association with other systemic autoimmune diseases. Systemic manifestations of SS involve the musculoskeletal system. SS can be seen in association with both joint and muscle manifestations, including arthralgia and arthritis, as well as myopathy, which is usually asymptomatic. Besides, it may include bone metabolic disorders, fatigue and fibromyalgia. The diagnosis of Sjögren’s syndrome is based on characteristic clinical signs and symptoms. The etiology and pathogenesis of SS is elusive and has not yet been clarified. There is no curative treatment for SS, thus the aim in the treatment of SS is to alleviate the symptoms.

Osteoarthritis (OA) is a condition with high prevalence worldwide. OA affects not only the articular cartilage, but the entire joint, including the subchondral bone, ligaments, capsule, synovial membrane and the periarticular muscles. Despite the fact that the risks associated with OA increase with age, it is not a part of the natural aging process. It typically involves the knee, hip, spine, hand and foot joints. Several factors play an important role in the pathogenesis of OA, including biomechanical factors, proinflammatory mediators and proteases. On the other hand, it was mostly the results of the studies conducted on the genetic, genomic and epigenetic aspects of OA, from among many of its underlying etiological factors, which shed light on the molecular processes involved in the etiopathogenesis of OA. As the mechanisms that cause joint tissue damage in OA come to light, the treatment of OA will go beyond just providing symptomatic relief. Consequentially, new treatments will emerge that will either slow or completely stop the progression of OA.